"Antiviral Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly.
| Descriptor ID |
D000998
|
| MeSH Number(s) |
D27.505.954.122.388
|
| Concept/Terms |
Antiviral Agents- Antiviral Agents
- Agents, Antiviral
- Antivirals
- Antiviral Drugs
- Drugs, Antiviral
|
Below are MeSH descriptors whose meaning is more general than "Antiviral Agents".
Below are MeSH descriptors whose meaning is more specific than "Antiviral Agents".
This graph shows the total number of publications written about "Antiviral Agents" by people in this website by year, and whether "Antiviral Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 1 | 0 | 1 |
| 1994 | 1 | 0 | 1 |
| 1995 | 2 | 0 | 2 |
| 1996 | 1 | 0 | 1 |
| 1997 | 3 | 0 | 3 |
| 1998 | 1 | 0 | 1 |
| 1999 | 1 | 2 | 3 |
| 2000 | 0 | 1 | 1 |
| 2002 | 2 | 0 | 2 |
| 2003 | 3 | 1 | 4 |
| 2004 | 1 | 1 | 2 |
| 2005 | 1 | 0 | 1 |
| 2006 | 2 | 0 | 2 |
| 2007 | 4 | 1 | 5 |
| 2008 | 2 | 1 | 3 |
| 2009 | 1 | 0 | 1 |
| 2010 | 2 | 1 | 3 |
| 2011 | 0 | 2 | 2 |
| 2012 | 1 | 3 | 4 |
| 2013 | 1 | 2 | 3 |
| 2015 | 1 | 2 | 3 |
| 2016 | 1 | 3 | 4 |
| 2017 | 2 | 2 | 4 |
| 2018 | 5 | 1 | 6 |
| 2019 | 4 | 0 | 4 |
| 2020 | 5 | 2 | 7 |
| 2021 | 1 | 4 | 5 |
| 2022 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antiviral Agents" by people in Profiles.
-
Premortem Skin Biopsy Assessing Microthrombi, Interferon Type I Antiviral and Regulatory Proteins, and Complement Deposition Correlates with Coronavirus Disease 2019 Clinical Stage. Am J Pathol. 2022 09; 192(9):1282-1294.
-
A Novel Full-Length Recombinant Human Complement Factor H (CFH; GEM103) for the Treatment of Age-Related Macular Degeneration Shows Similar In Vitro Functional Activity to Native CFH. Curr Eye Res. 2022 07; 47(7):1087-1093.
-
Whey-Derived Peptides at the Heart of the COVID-19 Pandemic. Int J Mol Sci. 2021 Oct 28; 22(21).
-
Identification of potent small molecule inhibitors of SARS-CoV-2 entry. SLAS Discov. 2022 01; 27(1):8-19.
-
Refractory and Resistant Cytomegalovirus After Hematopoietic Cell Transplant in the Letermovir Primary Prophylaxis Era. Clin Infect Dis. 2021 10 20; 73(8):1346-1354.
-
Insights into the modulation of the interferon response and NAD+ in the context of COVID-19. Int Rev Immunol. 2022; 41(4):464-474.
-
Underscoring the immense potential of chitosan in fighting a wide spectrum of viruses: A plausible molecule against SARS-CoV-2? Int J Biol Macromol. 2021 May 15; 179:33-44.
-
COVID-19: A review of therapeutic strategies and vaccine candidates. Clin Immunol. 2021 01; 222:108634.
-
Treatment of Hepatitis C Genotypes 1 to 5 in Sub-Saharan Africa Using Direct-Acting Antivirals. Am J Trop Med Hyg. 2020 11; 103(5):2083-2084.
-
Perspectives on mechanistic implications of ROS inducers for targeting viral infections. Eur J Pharmacol. 2021 Jan 05; 890:173621.